115
Views
1
CrossRef citations to date
0
Altmetric
Short Report

Healthcare Resource Consumption and Related Costs of Patients Estimated with Treatment-Resistant Depression in Italy

, , , , , , , , , , & ORCID Icon show all
Pages 629-635 | Published online: 05 Jul 2021

References

  • World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
  • Cepeda MS, Reps J, Fife D, Blacketer C, Stang P, Ryan P. Finding treatment-resistant depression in real-world data: how a data-driven approach compares with expert-based heuristics. Depress Anxiety. 2018;35(3):220–228. doi:10.1002/da.22705
  • Marcatili M, Sala C, Dakanalis A, et al. Human induced pluripotent stem cells technology in treatment resistant depression: novel strategies and opportunities to unravel ketamine’s fast-acting antidepressant mechanisms. Ther Adv Psychopharmacol. 2020;10:2045125320968331. doi:10.1177/2045125320968331
  • Murphy JA, Sarris J, Byrne GJ. A review of the conceptualisation and risk factors associated with treatment-resistant depression. Depress Res Treat. 2017;2017:1–10. doi:10.1155/2017/4176825
  • Clinical investigation of medicinal products in the treatment depression. European Medicines Agency; September 17, 2018. Available from: https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-treatment-depression. Accessed September 18, 2019.
  • Luchini F, Cosentino L, Pensabene L, Mauri M, Lattanzi L. Depressione resistente al trattamento: stato dell’arte Parte II. Trattamento. Riv Psichiatr. 2014;49(6):228–240. doi:10.1708/1766.19120
  • Gaynes BN, Asher G, Gartlehner G, et al. Definition of treatment-resistant depression in the medicare population. Agency for Healthcare Research and Quality (US); 2018. Available from: http://www.ncbi.nlm.nih.gov/books/NBK526366/. Accessed September 18, 2019.
  • Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 2019;19(1):247. doi:10.1186/s12888-019-2222-4
  • Li G, Zhang L, DiBernardo A, et al. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients. PLoS One. 2020;15(9):e0238843. doi:10.1371/journal.pone.0238843
  • Perrone V, Sangiorgi D, Andretta M, et al. Assessment of patients affected by treatment-resistant depression: findings from a Real-World Study in Italy. JPPD. 2020;04(03). doi:10.26502/jppd.2572-519X0098
  • Agenzia Italiana del Farmaco (AIFA). Guideline for the classification and conduction of the observational studies on medicines; 2010. Available from: https://www.agenziafarmaco.gov.it/ricclin/sites/default/files/files_wysiwyg/files/CIRCULARS/Circular%2031st%20May%202010.pdf. Accessed June 18, 2021.
  • Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr Med Res Opin. 2010;26(10):2475–2484. doi:10.1185/03007995.2010.517716
  • Amos TB, Tandon N, Lefebvre P, et al. Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-Cohort Study using a US commercial claims database. J Clin Psychiatry. 2018;79(2):24–32. doi:10.4088/JCP.17m11725
  • Zhdanava M, Kuvadia H, Joshi K, et al. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder. Curr Med Res Opin. 2020:1–11. doi:10.1080/03007995.2020.1844645
  • Johnston KM, Powell LC, Anderson IM, Szabo S, Cline S. The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. J Affect Disord. 2019;242:195–210. doi:10.1016/j.jad.2018.06.045
  • McIntyre RS, Millson B, Power GS. Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: economic burden and healthcare resource utilization. J Affect Disord. 2020;277:30–38. doi:10.1016/j.jad.2020.07.045